Answers are grounded in this paper and cite their sources.
Amongst all the proton pump inhibitors (PPI), the hepatic metabolism of rabeprazole is least dependent on the CYP4502C19 system. Rabeprazole is therefore the PPI least affected by CYP4502C19 genetic polymorphism. This unique feature of rabeprazole complements rabeprazole's fast onset of action, and may lead to profound and consistent inhibition of gastric acid secretion in the treatment of acid-related disorders.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: